X4 Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-0.697; its P/E ratio is -1.33; X4 Pharmaceuticals is scheduled to report earnings on August 1, 2024, and the estimated EPS forecast is

lt;0.01. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Income Statement	-
Total Revenue	-	$ 49.00K	$ 49.00K	$ 48.00K	$ 49.00K
Gross Profit	-	$ 49.00K	$ 49.00K	$ 48.00K	$ 49.00K
EBIT	$ -36.12M	$ -17.21M	$ -645.00K	$ -54.55M	$ -29.18M
EBITDA	$ -36.06M	$ -17.15M	-	-	$ 0.00
Net Income Common Stockholders	$ -51.77M	$ -19.13M	$ -2.31M	$ -55.71M	$ -24.02M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 80.87M	$ 114.22M	$ 141.68M	$ 141.31M	$ 93.41M
Total Assets	$ 112.18M	$ 147.26M	$ 173.29M	$ 173.40M	$ 123.42M
Total Debt	$ 58.27M	$ 3.71M	$ 3.96M	$ 5.04M	$ 5.11M
Net Debt	$ -22.59M	$ -110.50M	$ -137.72M	$ -136.27M	$ -88.30M
Total Liabilities	$ 111.15M	$ 96.16M	$ 105.70M	$ 105.86M	$ 72.73M
Stockholders Equity	$ 1.04M	$ 51.10M	$ 67.59M	$ 67.50M	$ 51.63M
Cash Flow	-
Free Cash Flow	$ -33.66M	$ -27.77M	-	-	-
Operating Cash Flow	$ -33.60M	$ -27.73M	$ -20.83M	-	-
Investing Cash Flow	$ -5.32M	$ -4.83M	$ -5.16M	-	-
Financing Cash Flow	-	$ 97.00K	$ 21.20M	-	-

Currency in USD

X4 Pharmaceuticals Earnings and Revenue History

Income Statement >

X4 Pharmaceuticals Debt to Assets

Balance Sheet >

X4 Pharmaceuticals Cash Flow

Cash Flow >

X4 Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing